Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | TYMP | P19971 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6607047 | 0.86 | VKORC1 (0.55) | MAPTKDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL6605495 | 0.84 | TYMP (0.63) | MAPTKDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL31716273 | 0.81 | TYMP (0.57) | MAPTKDM4EALDH1A1TDP1L3MBTL1 | |
| SCHEMBL5218977 | 0.81 | TYMP (0.57) | MAPTKDM4EALDH1A1TDP1L3MBTL1 | |
| SCHEMBL11673281 | 0.80 | HTR2B (0.65) | MAPTSMN1; SMN2TDP1CASP3SENP7 | |
| SCHEMBL28316267 | 0.78 | CYP11B1 (0.64) | MAPTKDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL28045622 | 0.75 | KDM4E (1.00) | MAPTKDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL10725654 | 0.74 | MAPT (0.67) | MAPTKDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL5222703 | 0.73 | CDC25B (0.58) | MAPTKDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL30184318 | 0.72 | LTA4H (0.42) | MAPTALDH1A1SMN1; SMN2TDP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105218506-B | A method of isocoumarin class compound is prepared by o-Halogen benzoic acids methyl esters and terminal alkyne | 湖南大学 | 2018-09-04 | — | — | CN | disclosed |
| EP-1397350-B1 | ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS | KUDOS PHARM LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| EP-1397350-A1 | ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS | Kudos Pharmaceuticals Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| US-6664269-B2 | Adminisetring isoquinolinone compounds for therapy of disease mediated by the enzyme poly(ADP- ribose)polymerase (\"PARP\") | MAYBRIDGE PLC (GB) | 2003-12-16 | — | — | US | disclosed |
| US-20030008896-A1 | Isoquinolinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2003-01-09 | — | — | US | disclosed |
| WO-2002090334-A1 | ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008896-A1 | Isoquinolinone derivatives | PARP1, PARP2, PARP3 | MAPT 1465/4885KDM4E 3073/4885ALDH1A1 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.